Publications by authors named "Odierna L"

Article Synopsis
  • This text indicates that the article with DOI: 10.1038/ncomms13660 has been corrected.
  • It suggests that there were errors or necessary updates made in the original publication.
  • The corrections are important for maintaining the accuracy and integrity of the research findings.
View Article and Find Full Text PDF
Article Synopsis
  • Syntaxin1A is organized into nanoclusters, which play a crucial role in the docking and priming of secretory vesicles in neurosecretory cells.
  • Researchers used advanced imaging techniques on Drosophila larvae to observe how activity changes the mobility and clustering of syntaxin1A in nerve terminals.
  • Results indicate that neurotransmitter release alters syntaxin1A's mobilization by affecting the stability of these nanoclusters, suggesting a dynamic mechanism regulating neurotransmitter release through lateral diffusion and trapping.
View Article and Find Full Text PDF

We prospectively studied 10 patients with stable exertional ischaemia, selected from a larger group of patients referred for suspected coronary artery disease or to detect residual ischaemia after myocardial infarction, to evaluate pharmacokinetic changes during chronic treatment with gallopamil and its correlation with clinical efficacy in patients with coronary artery disease. Our study consisted of a 1-week run-in single-blind placebo treatment and a 4-week single-blind gallopamil treatment. At the end of the run-in period patients underwent two different exercise tests, the first 2 hours and the second 7 hours after placebo administration.

View Article and Find Full Text PDF

We evaluated the efficacy and safety of gallopamil 150 mg daily in middle-aged and elderly patients with stable exertional ischemia, using a medium-term randomized double-blind cross-over placebo-controlled trial. Twenty middle-aged patients (52.8 +/- 6 years; range 38-61 years) and 14 elderly patients (67.

View Article and Find Full Text PDF

Our study evaluated the effects of verapamil in elderly patients with stable effort angina using a medium-term double-blind placebo-controlled protocol. Thirty-nine consecutive patients, 23 middle-age patients (50 +/- 6 years; range 38-60 years) and 16 elderly patients (66 +/- 2 years; range 65-70 years) with exertional angina were chosen. After a run-in period, both groups received treatment with either placebo or verapamil--360 mg daily--for 4 weeks.

View Article and Find Full Text PDF

We evaluated the acute therapeutic effects of the oral administration of nifedipine (10 mg) and diltiazem (120 mg) alone and in combination in 16 patients with effort angina. The 16 patients (13 men and three women; mean age 59 +/- 7 years) performed a symptom-limited bicycle exercise stress test 3 h after placebo or active substance administration. Maximal work load, exercise duration and time to 1 mm ST segment depression were significantly increased and ST depression at peak exercise was significantly decreased by the combination of drugs.

View Article and Find Full Text PDF

We have evaluated the biochemical and clinical parameters for early detection of their alterations in pregnant women with late preeclampsia. Eighty nine patients between 24 and 32 gestation weeks were studied. Fifteen of them (18%) developed arterial hypertension (mean 141.

View Article and Find Full Text PDF

Twenty-one patients with angiographic evidence of significant coronary artery disease, and positive dipyridamole echocardiographic test results at basal condition and after 7 days of placebo treatment were prospectively studied to see whether beta blockade modifies the effects of dipyridamole echocardiographic testing on regional myocardial contractility. Patients were randomized to propranolol (120 mg/day) or placebo treatment in 3 divided doses for 7 days, after which each patient crossed over to the alternate regimen. Dipyridamole-echocardiographic testing was repeated at the end of each treatment.

View Article and Find Full Text PDF

The antianginal effects of 360 mg/day of diltiazem were evaluated, using intrapatient comparisons, in a double/blind, randomized, placebo/controlled trial in 24 young patients (50 +/- 7 years) and in 16 elderly patients (67 +/- 3 years) with stable effort angina. All patients had angiographic documentation of significant coronary artery disease. An open-labelled, randomized, crossover design was employed.

View Article and Find Full Text PDF